Value of p63 and cytokeratin 5/6 as immunohistochemical markers for the differential diagnosis of poorly differentiated and undifferentiated carcinomas.

To facilitate the differential diagnosis of poorly differentiated metastatic carcinomas of unknown primary site, we evaluated p63 and cytokeratin (CK) 5/6 as immunohistochemical markers for squamous cell carcinomas. The study cases were as follows: squamous cell carcinoma of the lungs, head/neck, esophagus, cervix uteri, or anal canal, 73; non-squamous cell carcinomas of various primary sites, 141; and urothelial carcinoma, 20. We also tested 14 malignant mesotheliomas. Immunoreactivity for p63 was as follows: squamous cell carcinomas, 59 (81%); urothelial carcinoma, 14 (70%), most often with diffuse staining patterns; non-squamous cell carcinomas, 20 (14.2%), resulting in a specificity of 0.86 of p63 for squamous cell carcinomas. Coexpression of p63 and CK5/6 had a sensitivity of 0.77 and a specificity of 0.96 for squamous cell carcinomas. Increasing the minimal criterion of positive immunostaining for both markers to more than 50% of immunoreactive tumor cells resulted in a specificity of 0.99, although the sensitivity diminished to 0.66. All malignant mesotheliomas were negative for p63. Our data suggest that positive immunostaining for both p63 and CK5/6 in poorly differentiated metastatic carcinomas is highly predictive of a primary tumor of squamous epithelial origin.

[1]  R. Moll.  Cytokeratins as markers of differentiation in the diagnosis of epithelial tumors. , 1998, Sub-cellular biochemistry.

[2]  A. Yang,et al.  p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. , 1998, Molecular cell.

[3]  Benjamin Geiger,et al.  The catalog of human cytokeratins: Patterns of expression in normal epithelia, tumors and cultured cells , 1982, Cell.

[4]  P. Chu,et al.  Cytokeratin 7 and Cytokeratin 20 Expression in Epithelial Neoplasms: A Survey of 435 Cases , 2000, Modern Pathology.

[5]  A. Gown,et al.  Monoclonal antibodies to human intermediate filament proteins. III. Analysis of tumors. , 1985, American journal of clinical pathology.

[6]  T. Sun,et al.  Uroplakins, specific membrane proteins of urothelial umbrella cells, as histological markers of metastatic transitional cell carcinomas. , 1995, The American journal of pathology.

[7]  F. McKeon,et al.  Association of p63 with proliferative potential in normal and neoplastic human keratinocytes. , 1999, The Journal of investigative dermatology.

[8]  V. Devita,et al.  Cancer : Principles and Practice of Oncology , 1982 .

[9]  M. Dietel,et al.  Uroplakin III is a highly specific and moderately sensitive immunohistochemical marker for primary and metastatic urothelial carcinomas. , 2000, American journal of clinical pathology.

[10]  D. Hossfeld,et al.  Metastasen bei unbekanntem Primärtumor , 1997, Der Onkologe.

[11]  S. Hammar.  Metastatic adenocarcinoma of unknown primary origin. , 1998, Human pathology.

[12]  N. Ordóñez,et al.  Value of cytokeratin 5/6 immunostaining in distinguishing epithelial mesothelioma of the pleura from lung adenocarcinoma. , 1998, The American journal of surgical pathology.

[13]  R Montironi,et al.  p63 is a prostate basal cell marker and is required for prostate development. , 2000, The American journal of pathology.

[14]  R. Moll,et al.  Biological and prognostic significance of stratified epithelial cytokeratins in infiltrating ductal breast carcinomas , 1998, Virchows Archiv.

[15]  N. Ordóñez.  Thrombomodulin expression in transitional cell carcinoma. , 1998, American journal of clinical pathology.

[16]  M. Miettinen,et al.  Keratin 20: immunohistochemical marker for gastrointestinal, urothelial, and Merkel cell carcinomas. , 1995, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[17]  A. Gown,et al.  COORDINATE EXPRESSION OF CYTOKERATIN-7 AND CYTOKERATIN-20 DEFINES UNIQUE SUBSETS OF CARCINOMAS , 1995 .

[18]  Rodney T. Miller,et al.  Blocking of Endogenous Avidin-Binding Activity in Immunohistochemistry: The Use of Egg Whites , 1997 .

[19]  A. Norton,et al.  Brief, high‐temperature heat denaturation (pressure cooking): A simple and effective method of antigen retrieval for routinely processed tissues , 1994, The Journal of pathology.

[20]  A. Leong.  THE RELEVANCE OF ULTRASTRUCTURAL EXAMINATION IN THE CLASSIFICATION OF PRIMARY LUNG TUMOURS , 1982, Pathology.

[21]  The World Health Organization histological typing of lung tumours. Second edition. , 1982, American journal of clinical pathology.

[22]  J. Hainsworth,et al.  Treatment of patients with cancer of an unknown primary site. , 1993, The New England journal of medicine.

[23]  T. Crook,et al.  High level expression of ΔN-p63: a mechanism for the inactivation of p53 in undifferentiated nasopharyngeal carcinoma (NPC)? , 2000, Oncogene.

[24]  G. Steele,et al.  Cancer: Principles and Practice of Oncology , 1983 .

[25]  N. Ordóñez.  Value of thrombomodulin immunostaining in the diagnosis of mesothelioma , 1997, Histopathology.

[26]  T. Tot.  The cytokeratin profile of medullary carcinoma of the breast , 2000, Histopathology.

[27]  L. Weiss,et al.  Immunoreactivity for epithelial and neuroendocrine antibodies are useful in the differential diagnosis of lung carcinomas. , 2000, Human pathology.

[28]  J. Jen,et al.  Frequent gain of the p40/p51/p63 gene locus in primary head and neck squamous cell carcinoma , 2000, International journal of cancer.

[29]  C. Muir.  Cancer of unknown primary site , 1995, Cancer.

[30]  P. Saldiva,et al.  Large cell carcinoma of the lung. Ultrastructural and immunohistochemical features. , 1986, Chest.

[31]  J. Jen,et al.  AIS is an oncogene amplified in squamous cell carcinoma. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[32]  Np Wang.  Coordinate expression of cytokeratin 7 and 20 defines unique subsets of carcinomas , 1995 .

[33]  B. Wenig,et al.  Basaloid squamous cell carcinoma of the sinonasal tract , 1999, Cancer.